Sialic acid levels on CD63 were significantly lower in plasma from bladder cancer patients, accompanied by an elevated total CD63 level (Fig. 1M, N), suggesting that changes in sialic acids on sEV are not stem from the elevated sialylated CD63 in bladder cancer. The gene discussed is CD63; the disease is urinary bladder cancer.